Lumoral Implant Workflow | Biofilmkontrol ved implantatbehandling

Q: 51% with BOP

N = 200 · RANDOMIZED, PEER-REVIEWED · 2026 In Stage I–III periodontitis patients on supportive periodontal care (SPC), reduction in key measurments were greater with home-applied dual-light therapy as an adjunct to SPC than in SPC alone. At 6 months, 51% of participants with the SPC+dual-light had BOP<10%, versus 23% with SPC alone. At 6 months, 63% had visible plaque (VPI) <10% with the SPC+dual-light, versus 38% with SPC alone. The number of sites with PPD ≥4 mm was also lower with SPC+dual-light. Pakarinen S et al. Journal of Periodontology. 2026. DOI: 10.1002/jper.70082

Q: Str. mutans reduction

IN VITRO · PEER-REVIEWED · 2020 In a Streptococcus mutans biofilm model, a single dual-light exposure produced a four-log reduction in bacterial counts. More importantly for daily home use, repeated single-modality treatment allowed biofilm adaptation over time, whereas the dual-light combination prevented that adaptation and maintained its bactericidal effect across repeated exposures. In implant patients, where biofilm continuously reforms on implant surfaces and within the peri-implant sulcus, creating persistent and difficult-to-access microbial niches, the relevance of sustained efficacy across repeated exposures exceeds that of single-exposure performance. Nikinmaa S et al. PLoS ONE. 2020. DOI: 10.1371/journal.pone.0232775

Q: Significant BOP reduction in 2 weeks

N = 30 · RANDOMIZED, NON-PUBLISHED INTERIM RESULTS · 2026 In a randomized study on peri-implantitis patients, adjunctive use of Lumoral resulted in a consistent and statistically significant reduction in bleeding on probing at 2, 4, and 8 weeks of daily treatment. The treatment effect was equally evident in all six sites. The Lumoral use resulted in a rapid, sustained, and statistically significant reduction in key inflammatory cytokines (TNF-α, IL-6, and IL-1β). The control group showed non-significant changes. indicating effective suppression of inflammatory activity. ClinicalTrials.gov: NCT06859866

Præoperativ bakteriel belastning

Implantatsucces starter før kirurgien

Lumoral® hjælper med den præ-operative stabilisering før implantatkirurgien ved at kontrollere biofilm og inflammatorisk belastning i perioden fra behandlingen er aftalt til kirurgien kan begynde.

HOPE CP-Studie viser at Lumoral® i tillæg til omhyggelig tandpleje kan forkorte behandlingstiden markant.

Tidlig peri-implant inflammation

Implantater fejler sjældent på dag 1

Plak omkring healing abutments og protetiske konturer kan accelerere inflammatorisk respons i helingsfasen.

Lumoral® hjælper patienten med reduktion af bakterieloaded samt stimulerer heling og blodtilførelse i det kirurgiske felt.

Langsigtet risiko

Svigt mellem recalls

Peri-implant mucositis opstår ofte som et hjemmeplejeproblem længe før det bliver et kirurgisk problem.

Langtidssucces afhænger af en vedligeholdelsesprotokol patienten faktisk kan følge.

Lumoral® studier viser en høj anvendelsesfrekvens gennem hele studieforløbene.

Patienten tilbringer størstedelen af tiden uden for klinikken

Professionel behandling er afgørende – men den biologiske ændring opstår mellem besøgene. Implantatpatienter kan tilbringe måneder i en inflammatorisk risikozone før næste recall.

Kontroller biofilm mellem besøgene

Lumoral® kombinerer antibakterielt blåt lys med fotodynamisk terapi for at reducere plaque og inflammatorisk belastning omkring implantater.

ABL · 405 nm

Målretter plak-associerede bakterier via antibakterielt blåt lys.

APDT · 810 nm + ICG

ICG binder selektivt til plak og aktiveres af nær-infrarødt lys.

Velegnet til vedligeholdelse

Ingen antibiotikabaseret mekanisme. Designet til gentagen hjemmebrug.

BOP 4.7 → 1.8 ↓

N = 40 · PEER-REVIEWED · 2025

In patients with newly diagnosed peri-implant disease, home dual-light therapy, adjunctive to traditional home-care, reduced bleeding on probing from 4.7% to 1.8% over 4 weeks (p < 0.0001). The control group showed no significant change. aMMP-8 also decreased in the treatment group, while it remained unchanged in controls. Gum inflammation is a threat to aligner patients, and it can cause long-lasting problems.

Lähteenmäki H et al. Clinical and Experimental Dental Research. 2025. DOI: 10.1002/cre2.70146

51% with BOP<10%

N = 200 · RANDOMIZED, PEER-REVIEWED · 2026

In Stage I–III periodontitis patients on supportive periodontal care (SPC), reduction in key measurments were greater with home-applied dual-light therapy as an adjunct to SPC than in SPC alone. At 6 months, 51% of participants with the SPC+dual-light had BOP<10%, versus 23% with SPC alone. At 6 months, 63% had visible plaque (VPI) <10% with the SPC+dual-light, versus 38% with SPC alone. The number of sites with PPD ≥4 mm was also lower with SPC+dual-light.

Pakarinen S et al. Journal of Periodontology. 2026. DOI: 10.1002/jper.70082

Str. mutans reduction

IN VITRO · PEER-REVIEWED · 2020

In a Streptococcus mutans biofilm model, a single dual-light exposure produced a four-log reduction in bacterial counts. More importantly for daily home use, repeated single-modality treatment allowed biofilm adaptation over time, whereas the dual-light combination prevented that adaptation and maintained its bactericidal effect across repeated exposures. In implant patients, where biofilm continuously reforms on implant surfaces and within the peri-implant sulcus, creating persistent and difficult-to-access microbial niches, the relevance of sustained efficacy across repeated exposures exceeds that of single-exposure performance.

Nikinmaa S et al. PLoS ONE. 2020. DOI: 10.1371/journal.pone.0232775

Significant BOP reduction in 2 weeks

N = 30 · RANDOMIZED, NON-PUBLISHED INTERIM RESULTS · 2026

In a randomized study on peri-implantitis patients, adjunctive use of Lumoral resulted in a consistent and statistically significant reduction in bleeding on probing at 2, 4, and 8 weeks of daily treatment. The treatment effect was equally evident in all six sites. The Lumoral use resulted in a rapid, sustained, and statistically significant reduction in key inflammatory cytokines (TNF-α, IL-6, and IL-1β). The control group showed non-significant changes. indicating effective suppression of inflammatory activity.

ClinicalTrials.gov: NCT06859866